Re:NewCell Future Growth
Future criteria checks 2/6
Re:NewCell is forecast to grow earnings and revenue by 82% and 83% per annum respectively. EPS is expected to grow by 82.7% per annum. Return on equity is forecast to be 12.4% in 3 years.
Key information
82.0%
Earnings growth rate
82.7%
EPS growth rate
| Chemicals earnings growth | 38.0% |
| Revenue growth rate | 83.0% |
| Future return on equity | 12.4% |
| Analyst coverage | Low |
| Last updated | 22 Dec 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 1,398 | 13 | N/A | N/A | 3 |
| 12/31/2024 | 682 | -145 | N/A | N/A | 3 |
| 12/31/2023 | 260 | -445 | N/A | N/A | 3 |
| 9/30/2023 | 205 | -401 | -578 | -342 | N/A |
| 6/30/2023 | 124 | -408 | -786 | -355 | N/A |
| 3/31/2023 | 41 | -371 | -1,150 | -398 | N/A |
| 12/31/2022 | 14 | -300 | -1,278 | -398 | N/A |
| 9/30/2022 | 9 | -290 | -1,139 | -329 | N/A |
| 6/30/2022 | 6 | -213 | -1,006 | -263 | N/A |
| 3/31/2022 | 4 | -168 | -645 | -196 | N/A |
| 12/31/2021 | 4 | -133 | -430 | -118 | N/A |
| 9/30/2021 | 2 | -88 | -329 | -78 | N/A |
| 6/30/2021 | 1 | -80 | -181 | -60 | N/A |
| 3/31/2021 | 2 | -72 | -146 | -66 | N/A |
| 12/31/2020 | 1 | -69 | -85 | -52 | N/A |
| 9/30/2020 | 2 | -60 | -51 | -50 | N/A |
| 12/31/2019 | 1 | -38 | -32 | -31 | N/A |
| 12/31/2018 | N/A | -18 | -30 | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6QP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6QP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6QP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6QP's revenue (83% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: 6QP's revenue (83% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6QP's Return on Equity is forecast to be low in 3 years time (12.4%).